Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636293 | 0.90 | PKM (0.73) | PKMSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL5637386 | 0.87 | SMN1; SMN2 (0.60) | PKMSMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL5638964 | 0.87 | PKM (0.60) | PKMSMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL26932397 | 0.86 | SMN1; SMN2 (0.60) | PKMSMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL5637809 | 0.86 | PKM (0.63) | PKMSMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL4407221 | 0.82 | TDP2 (0.59) | PKMSMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL26538218 | 0.79 | PKM (0.67) | PKMSMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL8199493 | 0.78 | PKM (0.48) | PKMSMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL2585585 | 0.77 | PKM (1.00) | PKMLMNAALDH1A1MAPTTDP1 | |
| SCHEMBL4913167 | 0.77 | PKM (0.55) | PKMSMN1; SMN2LMNAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186745-B2 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1370527-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002070478-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | HYOU1, IDO1, OXER1 | PKM 4024/4885SMN1; SMN2 3083/4885LMNA 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.